Neurocrine Biosciences (NBIX) to Release Quarterly Earnings on Wednesday

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) is expected to be releasing its Q2 2025 earnings data after the market closes on Wednesday, July 30th. Analysts expect Neurocrine Biosciences to post earnings of $0.97 per share and revenue of $653.09 million for the quarter.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported $0.08 EPS for the quarter, missing analysts' consensus estimates of $0.70 by ($0.62). Neurocrine Biosciences had a net margin of 12.68% and a return on equity of 11.81%. The business had revenue of $572.60 million during the quarter, compared to the consensus estimate of $587.06 million. During the same period in the previous year, the business posted $1.20 EPS. The firm's revenue was up 11.1% on a year-over-year basis. On average, analysts expect Neurocrine Biosciences to post $4 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Neurocrine Biosciences Price Performance

Shares of NBIX traded down $2.02 during midday trading on Thursday, hitting $131.64. The stock had a trading volume of 885,761 shares, compared to its average volume of 732,545. Neurocrine Biosciences has a 1 year low of $84.23 and a 1 year high of $157.98. The firm has a market cap of $13.03 billion, a PE ratio of 45.31, a price-to-earnings-growth ratio of 1.37 and a beta of 0.24. The stock's 50 day moving average is $126.68 and its 200 day moving average is $121.38.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Jude Onyia sold 59,819 shares of the business's stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $130.46, for a total transaction of $7,803,986.74. Following the sale, the insider directly owned 18,289 shares in the company, valued at $2,385,982.94. This represents a 76.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Kevin Charles Gorman sold 9,613 shares of the business's stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $120.38, for a total transaction of $1,157,212.94. Following the sale, the director owned 514,596 shares in the company, valued at $61,947,066.48. This trade represents a 1.83% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 120,251 shares of company stock valued at $14,978,602 over the last three months. 4.80% of the stock is currently owned by company insiders.

Institutional Trading of Neurocrine Biosciences

A number of large investors have recently made changes to their positions in the company. Royal Bank of Canada increased its stake in shares of Neurocrine Biosciences by 36.7% during the first quarter. Royal Bank of Canada now owns 82,810 shares of the company's stock worth $9,158,000 after buying an additional 22,224 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Neurocrine Biosciences by 60.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,783 shares of the company's stock worth $1,647,000 after buying an additional 5,577 shares during the period. Empowered Funds LLC purchased a new stake in shares of Neurocrine Biosciences during the first quarter worth approximately $1,333,000. NewEdge Advisors LLC increased its stake in shares of Neurocrine Biosciences by 56.3% during the first quarter. NewEdge Advisors LLC now owns 7,630 shares of the company's stock worth $844,000 after buying an additional 2,747 shares during the period. Finally, Acadian Asset Management LLC increased its stake in shares of Neurocrine Biosciences by 14.3% during the first quarter. Acadian Asset Management LLC now owns 3,054 shares of the company's stock worth $337,000 after buying an additional 383 shares during the period. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have issued reports on NBIX. HC Wainwright dropped their target price on shares of Neurocrine Biosciences from $185.00 to $168.00 and set a "buy" rating on the stock in a report on Tuesday, April 22nd. Evercore ISI dropped their target price on shares of Neurocrine Biosciences from $190.00 to $185.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. The Goldman Sachs Group began coverage on shares of Neurocrine Biosciences in a report on Thursday, July 10th. They set a "buy" rating and a $182.00 target price on the stock. BMO Capital Markets increased their target price on shares of Neurocrine Biosciences from $96.00 to $115.00 and gave the stock a "market perform" rating in a report on Tuesday, May 6th. Finally, Guggenheim raised their price target on shares of Neurocrine Biosciences from $155.00 to $165.00 and gave the company a "buy" rating in a report on Tuesday, May 6th. Three equities research analysts have rated the stock with a hold rating and twenty-two have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $163.87.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.